Oncology/Hematology
Breast Cancer
More in Breast Cancer
In trial, datopotamab deruxtecan increased progression-free survival by 2 months
News, features, and commentary about cancer-related issues
25 drugs chosen so far comprise about a third of Medicare Part D spending on prescription drugs
Mortality hazard reduced by one third at 7 years versus trastuzumab
Greater burden of disease in younger folks and women, American Cancer Society projects
News, features, and commentary about cancer-related issues
New report emphasizes greater public awareness, education
News, features, and commentary about cancer-related issues
"We should not look at variant allele frequency to make a decision," said Virginia Kaklamani, MD
Hormone receptor-positive patients with high TMB may fare well with immunotherapy
News, features, and commentary about cancer-related issues
News, features, and commentary about cancer-related issues
Lack of biomarkers handicaps decision making in era of expanding treatment options
No improvement in survival or impact on recurrence, but pending studies leave door ajar
